Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
June 13 2017 - 4:30PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that the U.S. Patent and
Trademark Office has issued a patent for VTS-270, a novel and
well-characterized 2-hydroxypropyl-beta-cyclodextrin (HPβCD)
product, under investigation as an intrathecally administered
treatment for Niemann-Pick Disease Type C1 (NPC-1).
The patent, U.S. Patent No. 9,675,634, relates
to proprietary cyclodextrin compositions with a specific
fingerprint and purity profile that distinguish VTS-270 from other
HPβCD products. The patent expires in 2036.
“We’re very pleased with the issuance of this
patent, which protects the differentiated composition of VTS-270
and strengthens our intellectual property position,” said Peter
Greenleaf, Chairman and Chief Executive Officer, Sucampo
Pharmaceuticals. “The patent is further evidence of the
profile of VTS-270, which we believe may provide a much-needed
treatment for patients and families living with NPC-1.”
VTS-270, which is currently in a pivotal Phase
2b/3 trial, has been granted breakthrough therapy designation in
the U.S. and orphan designation in both the U.S. and EU.
Results from the pivotal trial are expected in mid-2018.
NPC-1 is a rare, progressive and ultimately lethal genetic
disorder affecting an estimated 2,000-3,000 patients globally.
Effective treatment of NPC remains a high unmet need, with no
approved products for patients in the U.S.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of highly specialized medicines. Sucampo
has a late-stage pipeline of product candidates in clinical
development for orphan disease areas, including VTS-270, a
2-hydroxypropyl-beta-cyclodextrin product with a specific
compositional fingerprint that has been granted orphan designation
in the U.S. and Europe and is in a pivotal Phase 2b/3 clinical
trial for the treatment of Niemann-Pick Disease Type C-1, a rare
progressive genetic disorder. VTS-270 also has been granted
breakthrough therapy designation in the U.S. Sucampo has an
exclusive option for the North American rights to CPP1-x/sulindac,
which is in Phase 3 development for the treatment of familial
adenomatous polyposis and has been granted orphan drug designation
in the U.S. The company has two marketed products – AMITIZA and
RESCULA. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, AMITIZA and RESCULA are registered trademarks of
Sucampo and its affiliates.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2023 to Sep 2024